Jay Lalezari

1.9k total citations
11 papers, 801 citations indexed

About

Jay Lalezari is a scholar working on Infectious Diseases, Virology and Hepatology. According to data from OpenAlex, Jay Lalezari has authored 11 papers receiving a total of 801 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 6 papers in Virology and 6 papers in Hepatology. Recurrent topics in Jay Lalezari's work include HIV Research and Treatment (6 papers), Hepatitis C virus research (6 papers) and HIV/AIDS drug development and treatment (6 papers). Jay Lalezari is often cited by papers focused on HIV Research and Treatment (6 papers), Hepatitis C virus research (6 papers) and HIV/AIDS drug development and treatment (6 papers). Jay Lalezari collaborates with scholars based in United States, United Kingdom and Germany. Jay Lalezari's co-authors include Edwin DeJesus, Mark Sulkowski, Michael S. Saag, Eric Lawitz, Ivy Song, Lewis McCurdy, Louis Sloan, Stephen C. Piscitelli, Sherene Min and Tamio Fujiwara and has published in prestigious journals such as PLoS ONE, Cancer Research and Journal of Hepatology.

In The Last Decade

Jay Lalezari

11 papers receiving 787 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jay Lalezari United States	9	432	398	362	191	126	11	801
Jan‐Christian Wasmuth Germany	16	173 0.4×	274 0.7×	185 0.5×	139 0.7×	47 0.4×	46	712
Axel Baumgarten Germany	19	718 1.7×	671 1.7×	571 1.6×	279 1.5×	39 0.3×	78	1.2k
Jacinta A. Holmes Australia	20	629 1.5×	612 1.5×	105 0.3×	42 0.2×	96 0.8×	51	947
Teresa Aldámiz‐Echevarría Spain	13	223 0.5×	277 0.7×	125 0.3×	97 0.5×	56 0.4×	47	483
Matthieu Carrière France	8	151 0.3×	173 0.4×	54 0.1×	152 0.8×	241 1.9×	9	511
Ulrike Mihm Germany	15	680 1.6×	635 1.6×	137 0.4×	29 0.2×	49 0.4×	42	850
Janusz Cianciara Poland	12	1.4k 3.2×	1.3k 3.3×	231 0.6×	73 0.4×	49 0.4×	33	1.5k
Sun Suk Kim South Korea	8	306 0.7×	230 0.6×	46 0.1×	40 0.2×	78 0.6×	21	510
Stacey R. Vlahakis United States	9	76 0.2×	134 0.3×	100 0.3×	267 1.4×	266 2.1×	10	537
Sue Ma United States	8	540 1.3×	379 1.0×	230 0.6×	59 0.3×	48 0.4×	11	709

Countries citing papers authored by Jay Lalezari

Since Specialization

Citations

This map shows the geographic impact of Jay Lalezari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Lalezari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Lalezari more than expected).

Fields of papers citing papers by Jay Lalezari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Lalezari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Lalezari. The network helps show where Jay Lalezari may publish in the future.

Co-authorship network of co-authors of Jay Lalezari

This figure shows the co-authorship network connecting the top 25 collaborators of Jay Lalezari. A scholar is included among the top collaborators of Jay Lalezari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay Lalezari. Jay Lalezari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Cristofanilli, Massimo, Marek Doležal, Jay Lalezari, et al.. (2020). Abstract CT233: Phase Ib/II study of leronlimab (PRO 140) combined with carboplatin in CCR5+ mTNBC patients. Cancer Research. 80(16_Supplement). CT233–CT233. 6 indexed citations

Younossi, Zobair M., Maria Stepanova, Andrei Racila, et al.. (2019). Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology. 18(2). 468–476.e11. 17 indexed citations

Thompson, Melanie, Michael S. Saag, Edwin DeJesus, et al.. (2015). A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. AIDS. 30(6). 869–878. 67 indexed citations

Rockstroh, Jürgen K., Mark Nelson, Christine Katlama, et al.. (2015). Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. The Lancet HIV. 2(8). e319–e327. 218 indexed citations

Ando, Dale, Gary Blick, Jay Lalezari, et al.. (2015). 25. A Dose Escalation Study of Cyclophophamide (CTX) to Enhance SB-728-T Engraftment. Molecular Therapy. 23. S11–S11. 1 indexed citations

Eron, Joseph J., Jay Lalezari, Jihad Slim, et al.. (2014). Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV‐1 co‐infected patients receiving atazanavir or raltegravir ART regimens. Journal of the International AIDS Society. 17(4S3). 19500–19500. 12 indexed citations

Gardiner, David, Jay Lalezari, Eric Lawitz, et al.. (2013). A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection. PLoS ONE. 8(5). e63818–e63818. 197 indexed citations

Taiwo, Babafemi, Edward P. Acosta, Patrick Ryscavage, et al.. (2013). Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 64(2). 167–173. 14 indexed citations

Hicks, Charles B., Patrick G. Clay, Robert Redfield, et al.. (2012). Safety, Tolerability, and Efficacy of KP-1461 as Monotherapy for 124 Days in Antiretroviral-Experienced, HIV Type 1-Infected Subjects. AIDS Research and Human Retroviruses. 29(2). 250–255. 13 indexed citations

10.

Rodríguez‐Torres, M., Eric Lawitz, Kris V. Kowdley, et al.. (2012). Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial. Journal of Hepatology. 58(4). 663–668. 85 indexed citations

11.

Min, Sherene, Louis Sloan, Edwin DeJesus, et al.. (2011). Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 25(14). 1737–1745. 171 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact